Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Nevada Rhapsido Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedAmbetter NevadaPolicy CP.PHAR.756

    Remibrutinib (Rhapsido)

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.PHAR.756 alerts

    Get alerted when Policy CP.PHAR.756 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Rhapsido in adult members with chronic spontaneous urticaria or symptomatic dermographism. It applies to providers seeking coverage under Ambetter Nevada commercial, marketplace/ICHRA, or Medicaid benefits.

    Policy Summary
    PayerAmbetter Nevada
    PolicyRemibrutinib (Rhapsido)
    Policy CodePolicy CP.PHAR.756
    Change TypeModified
    Effective DateDec 1, 2025
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation confirming the covered diagnosis, specialist involvement, age, prior antihistamine-based treatment failures or contraindications, no concurrent Dupixent or Xolair, and dosing no greater than 50 mg per day.
    SourceLink
    POLICY UPDATE CHANGES

    The required antihistamine trial dose was revised from the maximum indicated dose to the maximum tolerated dose, allowing up to four-fold standard dosing consistent with practice guidelines.

    The revision history records addition of a newly approved symptomatic indication.

    The revision history records addition of the ICHRA line of business.

    References were reviewed and updated during the 4Q 2026 annual review.

    2FDA-approved covered indications
    18 yearsMinimum age
    50 mg/dayMaximum daily dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 monthsApproval duration
    2 weeksRequired trial duration
    Up to 4-foldAntihistamine dose allowance

    Coverage Criteria

    Initial Therapy: Chronic Spontaneous Urticaria

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of chronic spontaneous urticaria (CSU).
    • Prescribed by or in consultation with a dermatologist, immunologist, or allergist.
    • Age is ≥ 18 years.
    • ONE of the following

      • For Illinois HIM requests only: Failure of one antihistamine at maximum tolerated doses (up to 4 times the standard dose) used for ≥ 2 weeks, unless clinically significant adverse effects are experienced or all are contraindicated.
      • For all other requests: BOTH of the following

        • Failure of two antihistamines, including one second-generation antihistamine (e.g., cetirizine, levocetirizine, fexofenadine, loratadine, or desloratadine), at maximum tolerated doses (up to 4 times the standard dose), each used for ≥ 2 weeks, unless clinically significant adverse effects are experienced or all are contraindicated.
        • Failure of a leukotriene modifier (LTRA) in combination with an antihistamine at maximum tolerated doses (up to 4 times the standard dose) for ≥ 2 weeks, unless clinically significant adverse effects are experienced or all are contraindicated.
    • Rhapsido is not prescribed concurrently with Dupixent or Xolair.
    • Dose does not exceed 50 mg (2 tablets) per day.

    Initial Therapy: Symptomatic Dermographism

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of symptomatic dermographism, a subtype of chronic inducible urticaria also known as urticaria factitia or dermographic urticaria.
    • Diagnosis is confirmed by provocation testing (e.g., Dermographic Tester or FricTest).
    • Prescribed by or in consultation with a dermatologist, immunologist, or allergist.
    • Age is ≥ 18 years.
    • ONE of the following

      • For Illinois HIM requests only: Failure of one antihistamine at maximum tolerated doses (up to 4 times the standard dose) used for ≥ 2 weeks, unless clinically significant adverse effects are experienced or all are contraindicated.

    Continuation Therapy: Chronic Spontaneous Urticaria or Symptomatic Dermographism

    Covered when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • Member is currently receiving medication via the Centene benefit or has previously met initial approval criteria.
      • Member is currently receiving medication and is enrolled in a state and product with continuity-of-care regulations; refer to state-specific addenda CC.PHARM.03A and CC.PHARM.03B.
    • Member is responding positively to therapy.
    • Rhapsido is not prescribed concurrently with Dupixent or Xolair.
    • If the request is for a dose increase, the new dose does not exceed 50 mg (2 tablets) per day.

    Other Diagnoses/Indications

    Coverage follows the applicable alternative pathway when at least ONE of the following is met:

    ONE of the following

    • If the drug has recently (within the last 6 months) undergone a label change not yet reflected in this policy, refer to ONE of the following

      • For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), refer to the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, or CP.PMN.255 for Medicaid.
      • For drugs not on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), refer to the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, or CP.PMN.16 for Medicaid.
    • If the requested use (e.g., diagnosis, age, or dosing regimen) is NOT specifically listed under Section III (Diagnoses/Indications for which coverage is NOT authorized) and the label-change criterion above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid.

    Non-FDA-approved indications that are not addressed in this policy are not authorized for coverage unless there is sufficient documentation of efficacy and safety according to the applicable off-label use policy—CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, or CP.PMN.53 for Medicaid—or according to applicable evidence of coverage documents.

    Concurrent prescribing of Rhapsido with Dupixent or Xolair is not authorized. This restriction applies to initial and continuation therapy for chronic spontaneous urticaria and symptomatic dermographism.

    Dose and Treatment Requirements

    Maximum Daily Dose
    Maximum daily dose50 mg per day
    Tablet equivalent2 tablets per day
    Applies toRhapsido dosing for chronic spontaneous urticaria and symptomatic dermographism
    Antihistamine Treatment Duration
    Minimum treatment durationAt least 2 weeks
    Treatment requirementEach required antihistamine must be used for at least 2 weeks
    Applies toRequired antihistamine trials for Rhapsido coverage

    Prior Authorization and Documentation

    Prior Authorization

    Initial Prior Authorization Required

    Submit an initial prior authorization request showing that the member meets all applicable approval criteria for the requested indication.

    • Document the diagnosis: chronic spontaneous urticaria (CSU) or symptomatic dermographism, as applicable.
    • Document prescribing by, or consultation with, a dermatologist, immunologist, or allergist.
    • Confirm the member is age ≥ 18 years.
    • Document required prior antihistamine and, for non-Illinois HIM CSU requests, leukotriene receptor antagonist (LTRA) combination therapy.
    • Confirm Rhapsido is not prescribed concurrently with Dupixent or Xolair.
    • Confirm the dose does not exceed 50 mg (2 tablets) per day.
    Prior Authorization

    Continuation Prior Authorization

    For continuation requests, document ongoing eligibility, positive response, safety, adherence, and continued need for therapy.

    Clinical Background

    Remibrutinib (Rhapsido) is a Bruton's tyrosine kinase inhibitor indicated for adults who remain symptomatic despite H1-antihistamine use for chronic spontaneous urticaria or symptomatic dermographism. Chronic spontaneous urticaria involves spontaneous wheals, angioedema, or both for more than 6 weeks; symptomatic dermographism is a form of chronic inducible urticaria triggered by physical stimulation.

    Key Definitions

    Chronic Spontaneous Urticaria
    DefinitionChronic spontaneous urticaria is characterized by spontaneous onset of wheals, angioedema, or both for more than 6 weeks
    ClassificationA form of chronic urticaria without a definite eliciting factor
    CausesMay occur due to known or unknown causes
    Symptomatic Dermographism
    DefinitionA subtype of chronic inducible urticaria in which definite physical triggers produce wheals, angioedema, or both
    Former namesUrticaria factitia or dermographic urticaria
    Trigger type

    Initial Therapy

    Chronic Spontaneous Urticaria

    Initial therapy for chronic spontaneous urticaria requires ALL of the following criteria and the applicable prior-treatment branch.

    Chronic spontaneous urticaria initial therapy

    • Applicable prior-treatment branch

      • Illinois HIM requests: Failure of one antihistamine at maximum tolerated doses, up to four times the standard dose, used for at least 2 weeks.At least 2 weeks; up to 4 times the standard dose
      • All other requests: Failure of two antihistamines, including one second-generation antihistamine, at maximum tolerated doses up to four times the standard dose, each used for at least 2 weeks, and failure of a leukotriene modifier in combination with an antihistamine at maximum tolerated doses up to four times the standard dose for at least 2 weeks.Each antihistamine >= 2 weeks; LTRA plus antihistamine >= 2 weeks; up to 4 times the standard dose

    Continuation Therapy

    Continuation Therapy

    Continued therapy is covered when ALL of the following criteria are met.

    Rhapsido continuation: Member is currently receiving Rhapsido through a Centene benefit or previously met the initial approval criteria, or is currently receiving Rhapsido and is enrolled in a state and product with continuity-of-care regulations; member is responding positively to therapy; Rhapsido is not prescribed concurrently with Dupixent or Xolair; and, if the request is for a dose increase, the new dose does not exceed 50 mg (2 tablets) per day.Maximum dose for an increase <= 50 mg/day

    Refer to state-specific addenda CC.PHARM.03A and CC.PHARM.03B for applicable continuity-of-care rules.

    Required Prior Treatment

    StepRequired therapyTreatment durationFailure criteria / exceptions
    1Two antihistamines, including one second-generation antihistamine, at maximum tolerated doses up to four times the standard dose, plus a leukotriene modifier (LTRA) combined with an antihistamine at maximum tolerated doses up to four times the standard dose.Each antihistamine: at least 2 weeks. LTRA plus antihistamine: at least 2 weeks.Failure is required unless clinically significant adverse effects occur or all required agents are contraindicated.
    StepRequired therapyTreatment durationFailure criteria / exceptions
    1Two antihistamines, including one second-generation antihistamine, at maximum tolerated doses up to four times the standard dose.At least 2 weeks for each antihistamine.Failure is required unless clinically significant adverse effects occur or all required agents are contraindicated.

    Rhapsido Quantity Limit

    Rhapsido Quantity Limits
    Dose25 mg
    FrequencyTwice daily
    Maximum daily dose50 mg per day, equivalent to 2 tablets per day
    Policy Summary
    PayerAmbetter Nevada
    PolicyRemibrutinib (Rhapsido)
    Policy CodePolicy CP.PHAR.756
    Change TypeModified
    Effective DateDec 1, 2025
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation confirming the covered diagnosis, specialist involvement, age, prior antihistamine-based treatment failures or contraindications, no concurrent Dupixent or Xolair, and dosing no greater than 50 mg per day.
    SourceLink
    On This Page
    Coverage CriteriaDose and Treatment RequirementsPrior Authorization and DocumentationClinical BackgroundKey DefinitionsInitial TherapyContinuation TherapyRequired Prior TreatmentRhapsido Quantity Limit
  1. For all other requests: Failure of two antihistamines, including one second-generation antihistamine (e.g., cetirizine, levocetirizine, fexofenadine, loratadine, or desloratadine), at maximum tolerated doses (up to 4 times the standard dose), each used for ≥ 2 weeks, unless clinically significant adverse effects are experienced or all are contraindicated.
  2. Rhapsido is not prescribed concurrently with Dupixent or Xolair.
  3. Dose does not exceed 50 mg (2 tablets) per day.
  4. LTRA Plus Antihistamine Duration
    Minimum treatment durationAt least 2 weeks
    Combination requiredLTRA in combination with an antihistamine
    Applies toRequired prior treatment for chronic spontaneous urticaria for applicable requests
    • Show that the member is currently receiving Rhapsido through the Centene benefit or previously met initial approval criteria, or is receiving the medication under applicable state and product continuity-of-care regulations.
    • Document that the member is responding positively to therapy.
    • Confirm Rhapsido is not prescribed concurrently with Dupixent or Xolair.
    • For a dose increase, confirm the new dose does not exceed 50 mg (2 tablets) per day.
    Step Therapy

    CSU Step Therapy

    For CSU requests other than Illinois HIM requests, document failure of both required treatment steps unless clinically significant adverse effects occurred or all applicable therapies are contraindicated.

    • Two antihistamines, including at least one second-generation antihistamine, such as cetirizine, levocetirizine, fexofenadine, loratadine, or desloratadine, at maximum tolerated doses up to four times the standard dose; each must be used for at least 2 weeks.
    • An LTRA used in combination with an antihistamine at maximum tolerated doses up to four times the standard dose for at least 2 weeks.
    Step Therapy

    Illinois HIM Exception

    For Illinois HIM requests for CSU or symptomatic dermographism, document failure of one antihistamine at the maximum tolerated dose, up to four times the standard dose, used for at least 2 weeks.

    • The requirement is waived only when clinically significant adverse effects are experienced or all applicable antihistamines are contraindicated.
    Step Therapy

    Symptomatic Dermographism Step Therapy

    For symptomatic dermographism requests other than Illinois HIM requests, document failure of two antihistamines, including one second-generation antihistamine, unless clinically significant adverse effects occurred or all applicable therapies are contraindicated.

    • Use maximum tolerated doses, up to four times the standard dose, for each antihistamine.
    • Document that each antihistamine was used for at least 2 weeks.
    Documentation Required

    Clinical Documentation Required

    Submit office chart notes, laboratory results, or other clinical information supporting that the member meets all applicable approval criteria.

    • Include documentation supporting the diagnosis, specialist involvement, age, prior treatment and response, provocation testing when applicable, requested dose, concurrent therapy review, and continuation eligibility.
    Documentation Required

    Provocation Testing

    For symptomatic dermographism, document confirmation of the diagnosis by provocation testing.

    • Acceptable examples include a Dermographic Tester or FricTest; comparable testing may also be submitted.
    • The clinical record should identify the testing performed and its result.
    Denial Risk

    Initial Approval Denial Risks

    Requests may be denied when initial approval requirements are not satisfied or cannot be substantiated.

    • Diagnosis is not established or does not match a covered indication.
    • Required specialist prescribing or consultation, age ≥ 18 years, or applicable prior-treatment requirements are not met.
    • Required antihistamine, LTRA combination therapy, or Illinois HIM exception documentation is absent or inadequate.
    • The requested dose exceeds 50 mg (2 tablets) per day.
    • Rhapsido is prescribed concurrently with Dupixent or Xolair.
    Denial Risk

    Unaddressed Non-FDA-Approved Use

    Coverage for a non-FDA-approved indication not addressed by this policy is not authorized unless sufficient efficacy and safety documentation supports the use under the applicable off-label policy or evidence of coverage documents.

    • For recently changed labeling not yet reflected in the policy, refer to the applicable formulary or non-formulary policy for the line of business.
    • For other unlisted uses, refer to CP.CPA.09, HIM.PA.154, or CP.PMN.53, as applicable.
    Denial Risk

    Continuation Approval Denial Risks

    Continuation requests may be denied when ongoing eligibility, response, safety, adherence, or treatment-need requirements are not met.

    • The member does not currently receive the medication through the Centene benefit, has not previously met initial criteria, and is not eligible under applicable continuity-of-care regulations.
    • Positive response to therapy is not documented.
    • Concurrent Dupixent or Xolair use is identified.
    • A requested dose increase exceeds 50 mg (2 tablets) per day.
    Specific, definite physical stimulation
    LTRA
    AbbreviationLTRA
    MeaningLeukotriene modifier
    Use in treatmentUsed in combination with an antihistamine for the required treatment trial

    Symptomatic Dermographism

    Initial therapy for symptomatic dermographism requires ALL of the following criteria and the applicable antihistamine-treatment branch.

    Symptomatic dermographism initial therapy

    • Applicable antihistamine-treatment branch

      • Illinois HIM requests: Failure of one antihistamine at maximum tolerated doses, up to four times the standard dose, used for at least 2 weeks.At least 2 weeks; up to 4 times the standard dose
      • All other requests: Failure of two antihistamines, including one second-generation antihistamine, at maximum tolerated doses up to four times the standard dose, each used for at least 2 weeks.Each antihistamine >= 2 weeks; up to 4 times the standard dose